Nucala (mepolizumab) effectively induced remission in about half of patients with eosinophilic granulomatosis with polyangiitis (EGPA) that relapsed or did not respond to treatment, according to results from a Phase 3 clinical trial (NCT02020889). The study found that Nucala reduced…
News
Recent Posts
- Mirador licenses long-acting antibody therapy for AAV development
- Embracing the power of many in life with ANCA vasculitis
- Kidney biopsy findings linked to recovery after severe AAV kidney injury
- Why a loss of hearing is a common but overlooked vasculitis warning sign
- Community tips to make navigating ANCA vasculitis care a little easier